Last verified: April 2026

Acute Cardiovascular Effects — The First Hour

Cannabis produces well-characterized acute cardiovascular effects, primarily mediated through CB1 receptor activation in the autonomic nervous system. Within minutes of inhalation, THC triggers a sympathetic surge that increases heart rate by 20–100% above baseline — a dose-dependent tachycardia that can persist for 2–3 hours. Simultaneously, peripheral vasodilation reduces systemic vascular resistance, producing orthostatic hypotension (the lightheadedness experienced when standing up quickly after cannabis use).

For young, healthy individuals, these effects are typically benign and transient. With regular use, tolerance to tachycardia develops robustly — chronic daily users show minimal heart rate elevation from the same doses that produce dramatic tachycardia in cannabis-naive individuals. But for individuals with pre-existing cardiovascular disease, the acute sympathetic activation may pose a genuine trigger risk.

The landmark study is Mittleman et al. (2001), published in Circulation. Using the Determinants of Myocardial Infarction Onset Study methodology, Mittleman interviewed 3,882 patients within four days of acute myocardial infarction (MI) about their activities in the hours preceding the event. The finding: the risk of MI onset was elevated 4.8-fold (95% CI: 2.4–9.5) in the first 60 minutes after cannabis use, declining rapidly thereafter.

The risk of myocardial infarction onset was elevated 4.8-fold (95% CI 2.4–9.5) over baseline in the 60 minutes after marijuana use.

Mittleman et al., Circulation 2001

Important caveats apply. The 4.8x figure comes from a relatively small number of cannabis-exposed events (124 patients reported cannabis use in the year preceding MI, and only 9 used within the hour before onset), producing wide confidence intervals. The absolute risk increase for a young person without cardiovascular disease remains very low. But for middle-aged or older patients with coronary artery disease, hypertension, or arrhythmia history, the acute sympathomimetic effects of cannabis represent a plausible and non-trivial trigger mechanism.

The Tashkin Paradox — Smoke Without Cancer

Donald Tashkin at UCLA has studied the pulmonary effects of cannabis smoking for more than three decades, producing what may be the most counterintuitive finding in cannabis science. The paradox can be stated simply: cannabis smoke contains approximately 50% more carcinogenic polycyclic aromatic hydrocarbons than tobacco smoke and deposits approximately 4 times more tar per puff (due to deeper inhalation and longer breath-holding) — yet large epidemiological studies consistently fail to find an association with lung cancer.

Tashkin’s 2006 case-control study, the largest population-based study of cannabis and lung cancer at the time, compared 611 lung cancer patients, 601 head and neck cancer patients, and 1,040 cancer-free controls in Los Angeles County. Even among the heaviest cannabis smokers (over 22,000 lifetime joints), there was no increased risk of lung cancer. In fact, the point estimates for the heaviest users were slightly below 1.0 (i.e., suggestive of a protective effect), though this did not reach statistical significance.

How can a carcinogen-laden smoke not cause cancer? The leading hypothesis involves THC’s known antitumorigenic properties at the cellular level. In vitro and animal studies show that cannabinoids can induce apoptosis (programmed cell death) in transformed cells, inhibit angiogenesis, and suppress tumor cell migration. Tashkin has proposed that THC may be acting as a chemotherapeutic counterbalance to the carcinogenic effects of combustion byproducts — the smoke causes cellular damage, but cannabinoids eliminate the damaged cells before they can become malignant.

This hypothesis remains unproven, and the Tashkin paradox does not mean cannabis smoking is safe for the lungs. Cannabis smoking clearly causes chronic bronchitis symptoms (cough, sputum production, wheezing), airway inflammation, and histopathological changes in bronchial epithelium. It is associated with an increased risk of large-airway disease. What it apparently does not do, based on decades of evidence, is cause the specific pattern of small-cell or squamous-cell carcinoma that tobacco so reliably produces.

Cannabinoid Hyperemesis Syndrome — The TRPV1 Connection

Cannabinoid Hyperemesis Syndrome (CHS) is a paradoxical condition in which chronic cannabis users develop cyclical episodes of severe nausea, intractable vomiting, and diffuse abdominal pain — paradoxical because cannabis is well-established as an antiemetic. CHS was first described in Australian case series by Allen et al. (2004) and was initially dismissed as an artifact, but it is now recognized as a genuine clinical entity with increasing prevalence.

The hallmark of CHS is compulsive hot bathing or showering — patients report that immersion in hot water is the only intervention that reliably alleviates symptoms during acute episodes. This pathognomonic behavior provided the clue to the underlying mechanism: TRPV1 (transient receptor potential vanilloid 1) desensitization.

TRPV1 is the capsaicin receptor — the same ion channel activated by chili peppers. It is also activated by anandamide and plays a role in the regulation of nausea and body temperature. The current model proposes that chronic THC exposure progressively desensitizes TRPV1 channels in the gastrointestinal tract, eventually disrupting the normal antiemetic signaling that endocannabinoids provide through this channel. Hot water temporarily reactivates TRPV1, providing transient relief. This model also explains why topical capsaicin (0.075% cream) applied to the abdomen has shown efficacy in emergency department treatment of CHS — it directly agonizes the desensitized TRPV1 channels.

The epidemiological trajectory of CHS is alarming. Emergency department visits for CHS have risen from approximately 4.4 per 100,000 visits to 33.1 per 100,000 in states with legal cannabis, according to data published in JAMA Network Open. Whether this represents a true increase in incidence (driven by higher-potency products and greater use frequency), increased recognition and diagnosis, or both remains debated. The condition resolves completely with sustained cannabis cessation — typically within 1–2 weeks — and recurs reliably with resumption of use.

Vaping Lung Injury — EVALI

In 2019, the E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI) outbreak caused 2,807 hospitalizations and 68 deaths across the United States, primarily among young adults using THC-containing vape cartridges. The CDC identified vitamin E acetate — a lipid diluent added to illicit and some regulated THC vape oils — as the primary cause. Vitamin E acetate interferes with pulmonary surfactant function and causes chemical pneumonitis when inhaled.

EVALI was not a consequence of cannabis itself but of an adulterant in an unregulated manufacturing process. Regulated cannabis markets that test for vitamin E acetate have not seen comparable outbreaks. The episode illustrated the public health consequences of prohibition-driven unregulated markets: when consumers cannot trust the supply chain, adulterants enter the product at every level.

Clinical Implications — Risk Stratification

The cardiovascular and pulmonary evidence supports a risk-stratified approach rather than blanket warnings:

• Young, healthy individuals — acute cardiovascular risks are minimal; chronic bronchitis from smoking is the primary pulmonary concern; vaporization of flower (not oil concentrates) substantially reduces respiratory irritant exposure
• Patients with cardiovascular disease — the Mittleman data suggest avoiding cannabis within the context of unstable angina, recent MI, or uncontrolled hypertension; if cannabis is used, low-dose oral or sublingual routes avoid the acute sympathetic surge of inhalation
• Heavy daily users — CHS risk increases with frequency and duration; patients presenting with cyclical vomiting and compulsive hot bathing should be screened for CHS and counseled that cessation is the only definitive treatment
• Immunocompromised patients — Aspergillus contamination of cannabis flower can cause fatal invasive pulmonary aspergillosis; this population should use only lab-tested products or non-inhalation routes